<DOC>
	<DOCNO>NCT02094053</DOCNO>
	<brief_summary>The purpose double-blind , placebo-controlled , comparative study open-label extension study confirm efficacy safety E2020 subject Down syndrome regression symptom disabled activity daily live .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled Comparative Study Open-label Extension Study Confirm Efficacy Safety E2020 Subjects With Down Syndrome Having Regression Symptoms Disabled Activities Daily Living .</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , multiple-dose ( two dos ) , placebo-controlled , parallel-group comparative study follow open-label extension study E2020 subject Down syndrome regression disable ADL . A total 60 subject randomize one three dose group ( 1:1:1 ) receive 3 mg E2020 , 5 mg E2020 , placebo 24 week base total score Body Functionality Checklist , sex , study site allocation factor . This study consist Pre-randomization Phase ( 4 week ) , Double-blind Phase ( 28 week ) , Extension Phase ( 24 week ) . The Double-blind Phase include 24-week treatment period plus 4-week transition period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria At enrollment Prerandomization Phase 1 . With definitive diagnosis Down syndrome 2 . Have great equal 3 follow 4 symptom among 9 item accord diagnostic criterion issue Intractable Diseases Treatment Research Program 2010 ( Research paper Intractable Diseases Treatment Research Program ; Survey Sudden Regression ( 21 trisomy ) Preparation Diagnostic Criteria . ) Motor retardation , mutism , social withdrawal ( homeboundness ) , sleep disorder 3 . Insufficiently improve environmental adjustment psychotherapy include counsel great equal 8 week enrollment 4 . Have suspect diagnosis neuropsychiatric disorder without sufficient effect disease even medical treatment great equal 8 week enrollment . 5 . A total score Body Functionality Checklist ( 51 item ) lesser equal 210 enrollment 6 . Aged 15 39 year inclusive 7 . Males females 8 . Must family member caregiver provide write informed consent able spend 3 day week subject ( least 4 hour per day ) able support subject study provide necessary study information subject , assist treatment compliance , accompany subject schedule visit , support studyrelated test efficacy safety assessment throughout study period 9 . Males females childbearing potential must practice highly effective contraception 10 . Able comply schedule study visit accord investigator 's instruction 11 . Able visit schedule assessment ( except walk difficulty due development regression ) 12 . Submitted write inform consent study entry ( obtain subject much possible ; mandatory legal guardian ) Exclusion Criteria At enrollment Prerandomization Phase 1 . Suspected progressive neuropsychiatric disease ( e.g. , neurodegenerative disorder progressive tumor ) evidence MRI CT within 1 year Prerandomization Phase ( test within 1 year Prerandomization Phase , reconfirm Prerandomization Phase ) . 2 . Have history significant neurological disorder stroke , brain tumor , encephalitis , meningitis , normal pressure hydrocephalus , brain trauma accompany unconsciousness , experience brain surgery cause unsolved deficiency 3 . Previously diagnose autism 4 . With evidence atlantoaxial subluxation , underwent surgical operation atlantoaxial subluxation within 2 year 5 . Have seizure symptom within 2 year use antiepileptic drug within 1 year enrollment Prerandomization Phase . 6 . With severe hear visual impairment may affect regression 7 . Have complication cardiac disease ( angina pectoris , congestive heart failure , bundle branch block , arrythmia ) peripheral vascular disease unstable condition 3 month enrollment Prerandomization Phase 8 . Have complication clinically significant active unstable disease gastrointestinal , hepatic , renal , respiratory , cardiovascular system 9 . Have history clinically significant gastrointestinal ulcer , bronchial asthma , obstructive pulmonary disease 10 . Have complication disease affect absorption , distribution , metabolism study drug ( e.g. , inflammatory colon disease , gastric ulcer , duodenal ulcer , hepatic disorder , serious lactose intolerance ) 11 . With present past history malignant tumor within 5 year informed consent ( except basal cell carcinoma , squamous cell carcinoma ) 12 . With complication history drug alcohol dependency within recent 10 year 13 . Have know hypersensitivity ingredient ( ) donepezil hydrochloride peperidine derivative 14 . Not meet criterion prohibit restrict concomitant medication , anticipate deviate criterion prohibit restrict concomitant medications/therapies study 15 . Pregnant lactate woman 16 . Have participate another clinical study receive study drug within 12 week enrollment study 17 . Have use donepezil hydrochloride participate clinical study E2020 receive E2020 past 18 . With history treatment Alzheimer 's type dementia 19 . With severe extrapyramidal disorder At enrollment Doubleblind Phase 20 . Suspected complication severe disease consider laboratory parameter enrollment Prerandomization Phase ( visit 1 ) safety protect opinion principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Down syndrome</keyword>
	<keyword>regression symptom</keyword>
	<keyword>disabled activity daily live</keyword>
</DOC>